TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29946179
Drug: Norfloxacin 400
Normalized name: norfloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin 400 mg daily
Study: 29946179
Drug: Ciprofloxacin once
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin once weekly
Study: 24461029
Drug: Curcumin formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin formulation with hydrophilic carrier, cellulosic derivatives and natural antioxidants (CHC)
Study: 24461029
Drug: Curcumin phytosome
Normalized name: Jarrow Formulas Curcumin Phytosome Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin phytosome formulation (CP)
Study: 24461029
Drug: Formulation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation with volatile oils of turmeric rhizome (CTR)
Study: 22124354
Drug: Caffeine-containing energy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine-containing energy drink (179 mg)
Study: 16352794
Drug: BNP levels
Normalized name: BNP
DrugBank: Nesiritide (DB04899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BNP levels >80 pg/mL at study entry
Study: 16352794
Drug: BNP levels
Normalized name: BNP
DrugBank: Nesiritide (DB04899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BNP levels >80 pg/mL at 4 months
Study: 16352794
Drug: BNP levels
Normalized name: BNP
DrugBank: Nesiritide (DB04899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BNP levels >80 pg/mL at 12 months
Study: 16352794
Drug: BNP levels
Normalized name: BNP
DrugBank: Nesiritide (DB04899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BNP levels <80 pg/mL at study entry and <80 pg/mL at 4 months
Study: 11926785
Drug: Split treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split treatment (human regular insulin at dinner and NPH insulin at bedtime)
Study: 11926785
Drug: Mixed treatment
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed treatment (a mixture of human regular and NPH insulin administered before dinner)
Study: 11926785
Drug: Split treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split treatment
Study: 11926785
Drug: Mixed treatment
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed treatment
Study: 10426343
Drug: Natural progesterone
Normalized name: NATURAL PROGESTERONE CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural progesterone (vaginal cream)
Study: 540460
Drug: 160 mg
Normalized name: nadolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg of long-acting propranolol
Study: 540460
Drug: 160 mg
Normalized name: nadolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg of standard propranolol
Study: 540460
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of sotalol
Study: 540460
Drug: 160 mg
Normalized name: nadolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg of oxprenolol
Study: 540460
Drug: 160 mg
Normalized name: nadolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg of slow-release oxprenolol
Study: 31805840
Drug: Narrative group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrative group therapy
Study: 18615497
Drug: CBT‐G/antidepressant combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT‐G/antidepressant combination
Study: 18615497
Drug: Antidepressant alone
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant alone
Study: 15241906
Drug: Prompt‐L‐Pop, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prompt‐L‐Pop, a 1‐step self‐etching primer ('all‐in‐one') (n = 52)
Study: 1995917
Drug: Total fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total fat intake (77 g per day)
Study: 17901162
Drug: Nurse led
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse led intermediate care package including initial pulmonary rehabilitation, self‐management education, written COPD action plan, monthly telephone calls, and 3 monthly home visits by a specialist nurse for 2 years
Study: 16823355
Drug: Maltodextrins ingestion
Normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maltodextrins ingestion (0.7 g x kg(-1) body mass)
Study: 10590187
Drug: Aspirin therapy
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin therapy (81 or 325 mg)
Study: 9547130
Drug: Antidepressants (general)
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants (general)
Study: 8396749
Drug: Simvastatin 5
Normalized name: simvastatin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 5 mg evening dose for 8 weeks
Study: 3453200
Drug: Quit Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quit Kit (self-administered smoking cessation program)
Study: 27447719
Drug: MF102 4 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF102 4 g/day
Study: 15564386
Drug: Relaxation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation therapy with an audiotape of classical music and ocean sounds during CNB
Study: 15564386
Drug: 0.5-mg of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5-mg of alprazolam administered orally 15 minutes before CNB
Study: 15564386
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (usual care, relaxation, medication)
Study: 28341877
Drug: Daily prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily prednisolone at 0.5 mg/kg for 5 days during URTI
Study: 25605425
Drug: Mechanical debridement
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical debridement (MDA) using carbon curettes and antiseptic therapy with chlorhexidine digluconate
Study: 23312291
Drug: standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard treatment according to Federal and local medical recommendations
Study: 8100428
Drug: Midazolam 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.15 mg/kg and saline
Study: 3209717
Drug: DA agonist
Normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA agonist (bromocriptine 5 mg orally)
Study: 3209717
Drug: DA antagonist
Normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA antagonist (haloperidol 5 mg intravenously)
Study: 3209717
Drug: Cholinergic agonist
Normalized name: PARASYMPATHOMIMETICS (CHOLINERGICS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholinergic agonist (physostigmine 2 mg intravenously)
Study: 3209717
Drug: Cholinergic antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cholinergic antagonist (benztropine 4 mg intravenously)
Study: 31302525
Drug: Daily emotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily emotion reporting
Study: 21295835
Drug: FSH (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: FSH (25 mg im, twice daily for 4 days)
Study: 21295835
Drug: eCG (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: eCG (1000 IU as a single i.m. dose)
Study: 11471907
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of melatonin 5 mg and zolpidem 10 mg
Study: 9555553
Drug: Epirubicin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin (40 mg/ml in normal saline) administered six times within 4 weeks after transurethral resection, followed by 11 additional monthly instillations of epirubicin
Study: 9555553
Drug: Epirubicin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin (40 mg/ml in normal saline) administered six times within 4 weeks after transurethral resection
Study: 8177458
Drug: Estro-progestin therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estro-progestin therapy
Study: 3308192
Drug: Orbital cobalt
Normalized name: Cobalt
DrugBank: Cobalt (DB14574)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orbital cobalt irradiation combined with retrobulbar methylprednisolone acetate (14 bilateral injections at 20-30 d intervals)
Study: 3308192
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with systemic corticosteroids and orbital radiotherapy
Study: 31774544
Drug: Micronized-isotretinoin 32
Normalized name: isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Micronized-isotretinoin 32 mg (fed state)
Study: 31774544
Drug: Lidose-isotretinoin 40
Normalized name: isotretinoin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidose-isotretinoin 40 mg (fed state)
Study: 31774544
Drug: Micronized-isotretinoin 32
Normalized name: isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Micronized-isotretinoin 32 mg (fasted state)
Study: 31774544
Drug: Lidose-isotretinoin 40
Normalized name: isotretinoin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidose-isotretinoin 40 mg (fasted state)
Study: 29506967
Drug: Self-administered Web-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered Web-based questionnaires (SAQ-Web)
Study: 29506967
Drug: Self-administered paper-based
Normalized name: paper birch pollen extract
DrugBank: Betula papyrifera pollen (DB10831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered paper-based questionnaires (SAQ-paper)
Study: 14671175
Drug: 1000 mg/6
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg/6 wk TU plus 20 mg/d CPA
Study: 14671175
Drug: 1000 mg/8
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg/8 wk TU plus 2 mg/d CPA
Study: 14671175
Drug: 1000 mg/8
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg/8 wk TU plus placebo
Study: 10882331
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg granisetron + DEX
Study: 10882331
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg granisetron + DEX
Study: 8993943
Drug: Simvastatin and
Normalized name: simvastatin and ezetimibe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin and Ciprofibrate combination
Study: 1730327
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC) + ethinyl estradiol (E2)
Study: 3881968
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 (0.75 mg, 1.5 mg, or 2.25 mg)
Study: 30316547
Drug: Individualised manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualised manual therapy plus guideline-based advice (10 sessions)
Study: 16236320
Drug: Lithium (300-1800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium (300-1800 mg/d)
Study: 11822473
Drug: Glutamine supplementation
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine supplementation (0.9 g x kg lean tissue mass(-1) x day(-1); n = 17)
Study: 11822473
Drug: Placebo (0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.9 g maltodextrin x kg lean tissue mass(-1) x day(-1); n = 14)
Study: 7746123
Drug: Short-term treatment
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term treatment (1 g of ciprofloxacin in a single daily dose for 2 days)
Study: 7746123
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (1 g of ciprofloxacin in two daily doses for 5 days)
Study: 2643037
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg once daily (with NSAIDs)
Study: 2643037
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg once daily (with NSAIDs)
Study: 2643037
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg twice daily (with NSAIDs)
Study: 1172813
Drug: Single daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single daily dose of allopurinol (300 mg)
Study: 1172813
Drug: Divided doses
Normalized name: Aluminum Zirconium Trichlorohydrex Gly 20 g in 100 g TOPICAL STICK [Dividends]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Divided doses of allopurinol (100 mg three times a day)
Study: 31307833
Drug: CND 32
Normalized name: CNDO-109
DrugBank: CNDO-109 (DB17290)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CND 32 mg/RSV 20 mg
Study: 31307833
Drug: RSV 20
Normalized name: RSV-IGIV
DrugBank: Respigam (DB17765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSV 20 mg
Study: 31307833
Drug: CND 32
Normalized name: CNDO-109
DrugBank: CNDO-109 (DB17290)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CND 32 mg
Study: 28578844
Drug: Dual-Mobility (DM)
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-Mobility (DM) implant
Study: 28578844
Drug: Single-Bearing (SB)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-Bearing (SB) implant
Study: 24085378
Drug: Group exercise
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group exercise therapy (90 min under physiotherapist guidance)
Study: 24085378
Drug: Group exercise
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group exercise therapy
Study: 19114852
Drug: Etravirine 400
Normalized name: Etravirine
DrugBank: Etravirine (DB06414)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Etravirine 400 mg twice daily
Study: 19114852
Drug: Etravirine 800
Normalized name: Etravirine
DrugBank: Etravirine (DB06414)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Etravirine 800 mg twice daily
Study: 15575933
Drug: Montelukast (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (10 mg once daily for 8 days)
Study: 15575933
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (250 microg twice daily for 8 days)
Study: 10460064
Drug: Propofol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (2 mg/kg bolus, 9 mg/kg/h infusion for 1 hour)
Study: 2135834
Drug: Prednisone therapy
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone therapy (10 week course)
Study: 498955
Drug: Exploratory laparotomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exploratory laparotomy with splenectomy after multiple chemotherapy
Study: 498955
Drug: Chemotherapy producing
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy producing complete clinical remission
Study: 31868879
Drug: Multimodality strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodality strategy consisting of radical hysterectomy/perioperative chemotherapy
Study: 31095683
Drug: Self-administered individual
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered individual treatment (SIT)
Study: 31095683
Drug: Group treatment
Normalized name: Allergenic Extracts Intradermal Kit [9 SO. GRASS GROUP TREATMENT SET]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group treatment (GT)
Study: 26470422
Drug: Longidaze in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Longidaze in addition to standard etiotropic antibacterial therapy
Study: 26470422
Drug: Standard etiotropic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard etiotropic antibacterial therapy
Study: 23357198
Drug: 1×10(10) IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1×10(10) IU of the vaccine
Study: 23357198
Drug: 1×10(9) IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1×10(9) IU of the vaccine
Study: 23357198
Drug: 1×10(8) IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1×10(8) IU of the vaccine
Study: 20689977
Drug: Client-centered, supportive-experiential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Client-centered, supportive-experiential group therapy (SET)
Study: 15466071
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human GH (0.025-0.04 mg/kg per day) plus conventional therapy
Study: 11495269
Drug: Aerosol therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosol therapy (streptomycin and steroids)
Study: 9692657
Drug: Fluvastatin 40
Normalized name: fluvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 40 mg every other day
Study: 7873824
Drug: Oral itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral itraconazole 200 mg daily for 7 days
Study: 7873824
Drug: Oral itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral itraconazole 100 mg for 15 days
Study: 3145677
Drug: Carboprost (15‐methyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboprost (15‐methyl PGF2 alpha) administered 8 hours after ethacridine lactate instillation
Study: 3145677
Drug: Carboprost (15‐methyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboprost (15‐methyl PGF2 alpha) administered 4 hours after ethacridine lactate instillation
Study: 3145677
Drug: Carboprost (15‐methyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboprost (15‐methyl PGF2 alpha) administered 2 hours after ethacridine lactate instillation
Study: 31845611
Drug: EEGer neurofeedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: EEGer neurofeedback software used for treatment
Study: 26160879
Drug: pomalidomide +
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: pomalidomide + low-dose dexamethasone
Study: 26160879
Drug: high-dose dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: high-dose dexamethasone
Study: 23747759
Drug: Prasugrel 5
Normalized name: prasugrel 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 5 mg in very elderly patients
Study: 23747759
Drug: Prasugrel 10
Normalized name: prasugrel 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 10 mg in nonelderly patients
Study: 23747759
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg in very elderly patients
Study: 18510659
Drug: tolterodine ER
Normalized name: tolterodine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: tolterodine ER (4 mg) + tamsulosin (0.4 mg)
Study: 18510659
Drug: tamsulosin (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: tamsulosin (0.4 mg)
Study: 2143596
Drug: Triatec 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triatec 2.5 mg
Study: 2143596
Drug: Triatec 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triatec 5 mg
Study: 2143596
Drug: Triatec 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triatec 10 mg
Study: 2143596
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 20 mg Lasilix and Triatec 5 mg
Study: 2143596
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment plan
Study: 25596468
Drug: Early invasive
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early invasive strategy (tirofiban infusion and coronary angiography within 6h)
Study: 9192504
Drug: Subcutaneous salmon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous salmon calcitonin (SCSCT) 50 IU/day for 30 days
Study: 9192504
Drug: Intranasal salmon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal salmon calcitonin (INSCT) 200 IU/day for 30 days
Study: 3905052
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment in low-risk tercile (VA population)
Study: 3905052
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment in high-risk tercile (VA population)
Study: 3905052
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment in CASS
Study: 3905052
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment in CASS
Study: 26896456
Drug: sarolaner (Simparica™)
Normalized name: sarolaner Chewable Tablet [Simparica]
Approvals — FDA: no, EMA: no, PMDA: no
Description: sarolaner (Simparica™) 2-4 mg/kg
Study: 26896456
Drug: afoxolaner (NexGard®)
Normalized name: afoxolaner Chewable Tablet [NexGard]
DrugBank: Afoxolaner (DB11369)
Approvals — FDA: no, EMA: no, PMDA: no
Description: afoxolaner (NexGard®) 2.5-6.8 mg/kg
Study: 24497345
Drug: CD133(+) BMC
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD133(+) BMC injection
Study: 20215545
Drug: Lapatinib (1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib (1,500 mg once daily or 500 mg twice daily)
Study: 11906798
Drug: 2 mg/day
Normalized name: Neupro 2 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/day buprenorphine
Study: 2103759
Drug: Diltiazem (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (60 mg t.d.s.)
Study: 30897567
Drug: Power Point
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Power Point Therapy (PPT) - 10 units of 10 min each
Study: 30897567
Drug: Power Point
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Power Point Therapy (PPT)
Study: 28940353
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 6000 mg/day for 28 days
Study: 27423164
Drug: Open treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open treatment following nonresponse to risperidone or placebo
Study: 25273659
Drug: No nasogastric
Approvals — FDA: no, EMA: no, PMDA: no
Description: No nasogastric intubation and early oral feeding (trial group)
Study: 22886837
Drug: HPβCD diclofenac
Normalized name: HP-beta-CD
DrugBank: Hydroxypropyl betadex (DB15379)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPβCD diclofenac 18.75 mg
Study: 22886837
Drug: HPβCD diclofenac
Normalized name: HP-beta-CD
DrugBank: Hydroxypropyl betadex (DB15379)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPβCD diclofenac 37.5 mg